Research ExplorerPublicationsRadiotherapy for Recurrent Medulloblastoma in Children and A...

Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation

Standard

Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation. / Adolph, Jonas E; Fleischhack, Gudrun; Tschirner, Sebastian; Rink, Lydia; Dittes, Christine; Mikasch, Ruth; Dammann, Philipp; Mynarek, Martin; Obrecht-Sturm, Denise; Rutkowski, Stefan; Bison, Brigitte; Warmuth-Metz, Monika; Pietsch, Torsten; Pfister, Stefan M; Pajtler, Kristian W; Milde, Till; Kortmann, Rolf-Dieter; Dietzsch, Stefan; Timmermann, Beate; Tippelt, Stephan; German GPOH HIT-Network.

In: CANCERS, Vol. 16, No. 11, 1955, 22.05.2024.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Adolph, JE, Fleischhack, G, Tschirner, S, Rink, L, Dittes, C, Mikasch, R, Dammann, P, Mynarek, M, Obrecht-Sturm, D, Rutkowski, S, Bison, B, Warmuth-Metz, M, Pietsch, T, Pfister, SM, Pajtler, KW, Milde, T, Kortmann, R-D, Dietzsch, S, Timmermann, B, Tippelt, S & German GPOH HIT-Network 2024, 'Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation', CANCERS, vol. 16, no. 11, 1955. https://doi.org/10.3390/cancers16111955

APA

Adolph, J. E., Fleischhack, G., Tschirner, S., Rink, L., Dittes, C., Mikasch, R., Dammann, P., Mynarek, M., Obrecht-Sturm, D., Rutkowski, S., Bison, B., Warmuth-Metz, M., Pietsch, T., Pfister, S. M., Pajtler, K. W., Milde, T., Kortmann, R-D., Dietzsch, S., Timmermann, B., ... German GPOH HIT-Network (2024). Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation. CANCERS, 16(11), [1955]. https://doi.org/10.3390/cancers16111955

Vancouver

Adolph JE, Fleischhack G, Tschirner S, Rink L, Dittes C, Mikasch R et al. Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation. CANCERS. 2024 May 22;16(11). 1955. https://doi.org/10.3390/cancers16111955

Bibtex

@article{e596f9b84b934171b05d3267ed2c1811,
title = "Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation",
abstract = "BACKGROUND: Radiotherapy (RT) involving craniospinal irradiation (CSI) is important in the initial treatment of medulloblastoma. At recurrence, the re-irradiation options are limited and associated with severe side-effects.METHODS: For pre-irradiated patients, patients with re-irradiation (RT2) were matched by sex, histology, time to recurrence, disease status and treatment at recurrence to patients without RT2.RESULTS: A total of 42 pre-irradiated patients with RT2 were matched to 42 pre-irradiated controls without RT2. RT2 improved the median PFS [21.0 (CI: 15.7-28.7) vs. 12.0 (CI: 8.1-21.0) months] and OS [31.5 (CI: 27.6-64.8) vs. 20.0 (CI: 14.0-36.7) months]. Concerning long-term survival after ten years, RT2 only lead to small improvements in OS [8% (CI: 1.4-45.3) vs. 0%]. RT2 improved survival most without (re)-resection [PFS: 17.5 (CI: 9.7-41.5) vs. 8.0 (CI: 6.6-12.2)/OS: 31.5 (CI: 27.6-NA) vs. 13.3 (CI: 8.1-20.1) months]. In the RT-na{\"i}ve patients, CSI at recurrence improved their median PFS [25.0 (CI: 16.8-60.6) vs. 6.6 (CI: 1.5-NA) months] and OS [40.2 (CI: 18.7-NA) vs. 12.4 (CI: 4.4-NA) months].CONCLUSIONS: RT2 could improve the median survival in a matched cohort but offered little benefit regarding long-term survival. In RT-na{\"i}ve patients, CSI greatly improved their median and long-term survival.",
author = "Adolph, {Jonas E} and Gudrun Fleischhack and Sebastian Tschirner and Lydia Rink and Christine Dittes and Ruth Mikasch and Philipp Dammann and Martin Mynarek and Denise Obrecht-Sturm and Stefan Rutkowski and Brigitte Bison and Monika Warmuth-Metz and Torsten Pietsch and Pfister, {Stefan M} and Pajtler, {Kristian W} and Till Milde and Rolf-Dieter Kortmann and Stefan Dietzsch and Beate Timmermann and Stephan Tippelt and {German GPOH HIT-Network}",
year = "2024",
month = may,
day = "22",
doi = "10.3390/cancers16111955",
language = "English",
volume = "16",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

RIS

TY - JOUR

T1 - Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation

AU - Adolph, Jonas E

AU - Fleischhack, Gudrun

AU - Tschirner, Sebastian

AU - Rink, Lydia

AU - Dittes, Christine

AU - Mikasch, Ruth

AU - Dammann, Philipp

AU - Mynarek, Martin

AU - Obrecht-Sturm, Denise

AU - Rutkowski, Stefan

AU - Bison, Brigitte

AU - Warmuth-Metz, Monika

AU - Pietsch, Torsten

AU - Pfister, Stefan M

AU - Pajtler, Kristian W

AU - Milde, Till

AU - Kortmann, Rolf-Dieter

AU - Dietzsch, Stefan

AU - Timmermann, Beate

AU - Tippelt, Stephan

AU - German GPOH HIT-Network

PY - 2024/5/22

Y1 - 2024/5/22

N2 - BACKGROUND: Radiotherapy (RT) involving craniospinal irradiation (CSI) is important in the initial treatment of medulloblastoma. At recurrence, the re-irradiation options are limited and associated with severe side-effects.METHODS: For pre-irradiated patients, patients with re-irradiation (RT2) were matched by sex, histology, time to recurrence, disease status and treatment at recurrence to patients without RT2.RESULTS: A total of 42 pre-irradiated patients with RT2 were matched to 42 pre-irradiated controls without RT2. RT2 improved the median PFS [21.0 (CI: 15.7-28.7) vs. 12.0 (CI: 8.1-21.0) months] and OS [31.5 (CI: 27.6-64.8) vs. 20.0 (CI: 14.0-36.7) months]. Concerning long-term survival after ten years, RT2 only lead to small improvements in OS [8% (CI: 1.4-45.3) vs. 0%]. RT2 improved survival most without (re)-resection [PFS: 17.5 (CI: 9.7-41.5) vs. 8.0 (CI: 6.6-12.2)/OS: 31.5 (CI: 27.6-NA) vs. 13.3 (CI: 8.1-20.1) months]. In the RT-naïve patients, CSI at recurrence improved their median PFS [25.0 (CI: 16.8-60.6) vs. 6.6 (CI: 1.5-NA) months] and OS [40.2 (CI: 18.7-NA) vs. 12.4 (CI: 4.4-NA) months].CONCLUSIONS: RT2 could improve the median survival in a matched cohort but offered little benefit regarding long-term survival. In RT-naïve patients, CSI greatly improved their median and long-term survival.

AB - BACKGROUND: Radiotherapy (RT) involving craniospinal irradiation (CSI) is important in the initial treatment of medulloblastoma. At recurrence, the re-irradiation options are limited and associated with severe side-effects.METHODS: For pre-irradiated patients, patients with re-irradiation (RT2) were matched by sex, histology, time to recurrence, disease status and treatment at recurrence to patients without RT2.RESULTS: A total of 42 pre-irradiated patients with RT2 were matched to 42 pre-irradiated controls without RT2. RT2 improved the median PFS [21.0 (CI: 15.7-28.7) vs. 12.0 (CI: 8.1-21.0) months] and OS [31.5 (CI: 27.6-64.8) vs. 20.0 (CI: 14.0-36.7) months]. Concerning long-term survival after ten years, RT2 only lead to small improvements in OS [8% (CI: 1.4-45.3) vs. 0%]. RT2 improved survival most without (re)-resection [PFS: 17.5 (CI: 9.7-41.5) vs. 8.0 (CI: 6.6-12.2)/OS: 31.5 (CI: 27.6-NA) vs. 13.3 (CI: 8.1-20.1) months]. In the RT-naïve patients, CSI at recurrence improved their median PFS [25.0 (CI: 16.8-60.6) vs. 6.6 (CI: 1.5-NA) months] and OS [40.2 (CI: 18.7-NA) vs. 12.4 (CI: 4.4-NA) months].CONCLUSIONS: RT2 could improve the median survival in a matched cohort but offered little benefit regarding long-term survival. In RT-naïve patients, CSI greatly improved their median and long-term survival.

U2 - 10.3390/cancers16111955

DO - 10.3390/cancers16111955

M3 - SCORING: Journal article

C2 - 38893076

VL - 16

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 11

M1 - 1955

ER -